Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Phase 2 Completed 24 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with locally recurrent or metastatic kidney cancer.

Timeline

Start: 2007-03
Primary completion: 2010-11
Completion: 2010-11

Outcome

Missed primary endpoint

paper no responses were observed in the 8 patients with papillary RCC. PMID 20711632 ↗

Publications

Results Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10.1007/s10637-010-9491-6. Epub 2010 Aug 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	50 mg	Oral